journal
MENU ▼
Read by QxMD icon Read
search

Chinese Clinical Oncology

journal
https://www.readbyqxmd.com/read/29860850/advances-in-treatment-and-care-in-metastatic-breast-cancer-mbc-are-there-mbc-patients-who-are-curable
#1
Masaya Hattori, Hiroji Iwata
Metastatic breast cancer (MBC) remains a largely incurable disease. The goals of treatment for MBC are still to maintain quality of life and prolong survival. However, some cases of MBC with a long-term relapse free survival occurs, implying that a small subset of MBC patients could become curable. Although it is a controversial issue of whether MBC can be cured, a more aggressive multidisciplinary approach to MBC with a curable intent may help improve MBC patient outcomes. The Earlier detection of metastatic disease by using modern imaging technologies may allow the detection of metastasis before cancer cells spread widely...
May 28, 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29860849/preoperative-radiotherapy-in-soft-tissue-sarcoma-from-general-guidelines-to-personalized-medicine
#2
Rick L Haas
BACKGROUND: This critical review aims to generate hypotheses when to adhere to guidelines and when it could be considered to individualize management of extremity soft tissue sarcomas. METHODS: Based upon peer-reviewed publications using a PubMed search on the MeSH headings "soft tissue sarcoma" AND "preoperative radiotherapy", data were compiled. Titles and abstracts screened for data including "fraction size AND/OR total dose AND/OR overall treatment time", "chemotherapy", "targeted agents AND/OR tyrosine kinase inhibitors", were screened as well as their respective reference...
May 23, 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764166/chimeric-antigen-receptor-t-cells-a-savior-with-a-high-price
#3
Gilberto de Lima Lopes, George R Nahas
Chimeric antigen receptor (CAR) T cells represent a medical and scientific breakthrough that may represent a paradigm for the future of personalized medicine in the age of cancer immunotherapy. As with many new cancer agents, such novel and incredible results come with a high price. At the time of the writing of this article, there are two CAR T cells available, Kymriah, produced by Novrtis with a price tag of US$475,000 and Yescarta produced by Gilead Pharmaceuticals with a price tag of US$373,000, neither price including the required hospital admission in order to administer the agent in addition to potential treatment of side effects...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764165/developing-academic-cancer-immunotherapy-in-asia-lessons-challenges-and-a-vision-for-thailand
#4
Nattiya Hirankarn
No abstract text is available yet for this article.
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764164/immunoregulatory-antigens-novel-targets-for-cancer-immunotherapy
#5
Ayako Wakatsuki Pedersen, Katharina L Kopp, Mads Hald Andersen, Mai-Britt Zocca
Historically, the development of cancer vaccines has focused on the central role of tumor antigens in eliciting tumor-specific immune responses, with limited success. Recent advances with checkpoint blockade approaches have brought about a renewed appreciation of the importance of targeting immune suppression in cancer patients. Here we discuss a novel approach to cancer immunotherapy, namely to target recently described T cells that uniquely control cells with immune suppressive functions. Accumulating evidence support the existence of self-reactive T cells that are specific to antigens derived from immunoregulatory proteins ("immunoregulatory antigens"), such as indoleamine 2,3-dioxygenase (IDO) and PD-L1...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764163/onward-and-upward-for-immuno-oncology
#6
Malcolm K Brenner
No abstract text is available yet for this article.
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764162/the-evolving-role-of-immune-oncology-in-colorectal-cancer
#7
Shaheenah Dawood
Metastatic colorectal cancer still remains an essentially non curable disease. However, with advances in chemotherapeutic and personalizing therapeutic approaches with the incorporation of targeted therapy such as anti-EGFR and anti-VEGF agents survival associated with metastatic colorectal cancer has certainly improved over the last two decades. Patients who are not amenable to surgery median survival remain approximately 2 to 3 years. In an attempt to improve prognostic outcome over the last decade research has focused on therapeutic options geared towards harnessing the immune system with success observed with the use of immune checkpoint inhibitors in the realm of a number of solid tumors including lung and renal cancer...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764161/the-emerging-role-of-oncolytic-virus-therapy-against-cancer
#8
Luke Russell, Kah-Whye Peng
This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer patients and we highlight the design features of selected examples, including adenovirus, herpes simplex virus, measles virus, retrovirus, reovirus, vaccinia virus, vesicular stomatitis virus...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764160/combinatorial-strategies-of-radiotherapy-and-immunotherapy-in-nasopharyngeal-carcinoma
#9
Eugenia L L Yeo, You Quan Li, Khee-Chee Soo, Joseph T S Wee, Melvin L K Chua
Immunotherapy and radiation therapy (RT) have each demonstrated clinical success in the treatment of nasopharyngeal carcinoma (NPC) when utilized independently. Several characteristics of NPC make it particularly well suited for immunotherapeutic strategies, such as the association with viral infections like EBV and human papilloma virus (HPV), upregulation of PD-L1 expression, and the high number of tumor infiltrating lymphocytes. Immune checkpoint blockade is one such immunotherapeutic strategy that is gaining popularity rapidly...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764159/emerging-role-of-immunotherapy-for-childhood-cancers
#10
Rupert Handgretinger, Patrick Schlegel
Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients. Moreover, cellular therapeutic approaches including chimeric antigen receptor (CAR) T-cells as well as natural killer (NK) cells have the potential to cure patients with so far incurable malignancies and are the basis for future new therapies for pediatric cancer...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764158/what-is-the-role-of-immunotherapy-in-breast-cancer
#11
Tira J Tan, Jack J Chan, Sulastri Kamis, Rebecca Alexandra Dent
The immune system plays a complex role in the recognition/prevention, early eradication as well as progression of cancer. Recently, we have witnessed great momentum in the field of immuno-oncology. Checkpoint inhibitors and chimeric antigen receptor T cell therapy have now entered the clinic, with impressive and durable clinical responses seen across a broad array of tumor types. There are several lines of evidence supporting the development of an immune targeted approach in breast cancer. Emerging data of early clinical trials evaluating monotherapy checkpoint inhibition have shown modest activity in breast cancer, in particular high grade and aggressive subtypes such as triple negative, human epidermal growth factor receptor 2 (HER2)-positive and luminal B breast cancers...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764157/cancer-immunotherapy-the-end-of-the-beginning
#12
Han Chong Toh
No abstract text is available yet for this article.
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29860848/immunotherapy-a-glimmer-of-hope-for-metastatic-prostate-cancer
#13
Vishal Jindal
Prostate cancer was the first cancer in which immunotherapy vaccine was approved by FDA in 2010 named Sipuleucel-T. No new immunotherapies have been approved since, as phase 3 trials didn't show any improvement in overall survival (OS) especially with immune checkpoint inhibitors. Currently tremendous amount of research is going on, in studying microenvironment of prostate cancer, finding new targets and biomarkers, and trying different combination therapies. Some of the new targets explored are VISTA and PARP inhibitors...
March 12, 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29486570/sweet-syndrome-as-the-leading-symptom-in-the-diagnosis-of-gastric-cancer
#14
Alberto Jacobo Cunquero-Tomás, Jose María Ortiz-Salvador, Vega Iranzo, Carlos Camps
Sweet syndrome is a neutrophilic infiltration of the papillary dermis, which may be associated with the presence of unknown malignancies, either haematological or solid tumours, in 1 out of 5 cases, being considered then as a paraneoplastic syndrome. We present the case of a male with a locally advanced gastric cancer whose final diagnosis was led by the prior debut of Sweet syndrome not explained by other causes.
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29486569/-cor-occidere-a-novel-strategy-of-targeting-the-tumor-core-by-radiosurgery-in-a-radio-and-chemo-resistant-intracranial-hemangiopericytoma
#15
You Quan Li, Eu Tiong Chua, Kevin L M Chua, Melvin L K Chua
Intracranial hemangiopericytomas (HPC) are chemotherapy- and radiotherapy (RT)-resistant. Here, we report on a novel stereotactic radiosurgery (SRS) technique-"Cor Occidere" (Latin), as a potential strategy of overcoming radioresistance of HPC. A 36-year old female presented to our clinic for consideration of a 3rd-course of RT for her recurrent cavernous sinus HPC, following previous cranial RT at 13 and 5 years prior, and a failed 9 months trial of bevacizumab/temozolomide. The tumor-adjacent brain stem and carotid artery risked substantial damage given the cumulative RT doses to these organs...
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29486568/comprehensive-clinical-genetics-care-for-patients-with-inherited-colorectal-cancer-associated-with-lynch-syndrome-western-and-asian-perspectives
#16
Yun Yang, Y Nancy You
Lynch syndrome (LS) arises from germline mutations that lead to defective functioning of the DNA mismatch repair (MMR) system. It is the most common cause of inherited colorectal cancer (CRC), and predisposes individuals to significantly elevated risks for extracolonic cancers. A sensitive and accurate diagnostic approach will enable proactive management of the proband and at-risk relatives in order to minimize their cancer burden. Comprehensive clinical genetics care should include personalized and tailored multidisciplinary oncologic care, with consideration for the extent of surgical resection, the choice of systemic agents, and the use of radiation...
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29486567/role-of-immune-checkpoint-inhibitors-and-novel-immunotherapies-in-uveal-melanoma
#17
Vishal Jindal
Uveal melanoma (UM) is one of the rare malignancies, which can be lethal despite local treatment. Treatment options available now can control UM in early stages, but once it metastasized to distant organs especially liver, prognosis is poor. Immune checkpoint inhibitors (ICIs) are the new revolutionary treatment in management of metastatic cutaneous melanoma. UM and cutaneous melanoma are similar as both of them derived from melanocytes but in terms of mutational load and expression of antigens they are distinct...
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29486566/pancreaticoduodenectomy-with-en-bloc-vein-resection-for-locally-advanced-pancreatic-cancer-a-case-series-without-venous-reconstruction
#18
Michele M Gage, Bradley N Reames, Aslam Ejaz, Johnathan Sham, Elliot K Fishman, Matthew J Weiss, Christopher L Wolfgang, Jin He
Resection with clean margin (R0 resection) is associated with better survival in patients with pancreatic cancer. Over the last decade, advancements in preoperative chemotherapy and radiation therapy in pancreatic cancer have led to expansion of indications for surgical resection. Current guidelines define pancreatic cancer with unreconstructable vascular involvement as locally advanced, or surgically unresectable. We present our experience in managing patients with locally advanced pancreatic cancer with a very unique series of patients who achieved R0 resection despite "unresectable" vascular involvement...
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307196/emilia-use-cunning-to-survive-cancer
#19
Joseph Gligorov, Sandrine Richard, Xavier Pivot
No abstract text is available yet for this article.
February 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29307195/choice-of-chemotherapy-regimen-for-early-her2-positive-breast-cancer-in-elderly-patients
#20
Noam Pondé, Evandro de Azambuja
No abstract text is available yet for this article.
February 2018: Chinese Clinical Oncology
journal
journal
47887
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"